No abstract available
Publication types
-
Comparative Study
-
Editorial
-
Comment
MeSH terms
-
Anastrozole
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal / administration & dosage*
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / genetics
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / mortality
-
Disease-Free Survival
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Humans
-
Lapatinib
-
Nitriles / administration & dosage
-
Nitriles / adverse effects
-
Prognosis
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Receptor, ErbB-2 / genetics
-
Receptor, ErbB-2 / metabolism*
-
Receptors, Estrogen / genetics
-
Receptors, Estrogen / metabolism*
-
Risk Assessment
-
Survival Analysis
-
Time Factors
-
Trastuzumab
-
Triazoles / administration & dosage
-
Triazoles / adverse effects
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Hormonal
-
Biomarkers, Tumor
-
Nitriles
-
Quinazolines
-
Receptors, Estrogen
-
Triazoles
-
Lapatinib
-
Anastrozole
-
Receptor, ErbB-2
-
Trastuzumab